UPDATE contains comment from Lilly
Eli Lilly has quit from a research and licence agreement with a Paris-listed clinical stage pharmaceutical company Adocia, the French company said on Friday.
Adocia wrote in its announcement that Lilly told them it has decided to break up the December 2014 Collaboration Research and License Agreement for the development of Adocia’s ultra-rapid insulin, known as BioChaperone Lispro. Adocia said it will still go on with preparation for the third phase of the study, as it saw improvement in performance versus Lilly’s Humalog.
This deal break up had no financial clause, and the rights that Adocia has licensed to Lilly will go back to the French company at no cost.
“We are extremely disappointed and surprised by Lilly’s decision to terminate the collaboration on our product which has demonstrated significant improvement in terms of performance vs Humalog across 6 clinical studies. Based upon this stage of development, we are convinced that BC Lispro can improve the lives of people with diabetes and Adocia will continue to prepare launch of phase 3 clinical trials while looking for a new partner,” said Gérard Soula, Chairman and CEO.
Lilly continues developing an alternative ultra-rapid insulin program
We’ve sent emails to both Lily and Adocia for more comments.
Gregory Andrew Kueterman from Eli Lilly responded byemail with this statement:
“Lilly has decided to cease our collaboration with Adocia in the development of BioChaperone Lispro. We will continue to develop an alternative ultra-rapid insulin program as part of our vision to offer a more complete range of medicines for people with diabetes.
Lilly continuously makes decisions about the allocation of resources to our development efforts. This decision was about making a choice.”